Carregant...
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells
Platinum compounds are the foundation of chemotherapy regimens for non-small cell lung cancer (NSCLC) despite poor response rates and limited response duration. It has been reported that tumor expression of excision repair cross-complementation group 1 (ERCC1), a key component in nucleotide excision...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3616665/ https://ncbi.nlm.nih.gov/pubmed/23275151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/carcin/bgs393 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|